Buprenorphine: prospective novel therapy for depression and PTSD

@article{Madison2020BuprenorphinePN,
  title={Buprenorphine: prospective novel therapy for depression and PTSD},
  author={Caitlin A. Madison and Shoshana Eitan},
  journal={Psychological Medicine},
  year={2020},
  volume={50},
  pages={881 - 893}
}
Abstract Background Depression and post-traumatic stress disorder (PTSD) are leading causes of disability and loss of life by suicide. Currently, there are less than satisfactory medical solutions to treat these mental disorders. Here, we explore recent preclinical and clinical studies demonstrating the potential of using buprenorphine to treat major depressive disorder, treatment-resistant depression, and PTSD. Method Bibliographic databases were searched to include preclinical and clinical… 
Inflammation‐driven brain and gut barrier dysfunction in stress and mood disorders
TLDR
An overview of inflammation‐related mechanisms involved in mood regulation and stress responses discovered using animal models is provided and promising targets worth further investigation are listed.
Long-term Follow-up Assessment of Opioid Use Outcomes among Individuals with Comorbid Mental Disorders and Opioid Use Disorder Treated with Buprenorphine or Methadone in a Randomized Clinical Trial.
TLDR
Among adults with comorbid opioid use disorder and mental disorders, treatment with buprenorphine-naloxone produced greater reductions in opioid use than treatment with methadone.
Gestational Buprenorphine Exposure Disrupts Dopamine Neuron Activity and Related Behaviors in Adulthood
TLDR
It is posited that gestational buprenorphine or oxycodone exposure can have profound effects on the mesolimbic dopamine system in adulthood, as well as potential long-lasting effects of opioid exposure during development.

References

SHOWING 1-10 OF 183 REFERENCES
Buprenorphine for the treatment of posttraumatic stress disorder
TLDR
Buprenorphine may help decrease PTSD symptoms more than SSRIs or opioids alone and Prospective studies are needed to determine whether these effects are reproducible.
The Anti-Suicidal Potential of Buprenorphine: A Case Report
TLDR
It is proposed that the unique pharmacodynamics of this drug served to stabilize dysregulated neural circuits, neurotransmitters, and neuropeptides, allowing the mitigation of pain, assuaging opioid cravings, easing depression, and resolving suicidal ideation.
Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?
TLDR
Buprenorphine/samidorphan has shown favorable results for efficacy and tolerability in premarketing studies evaluating its use as adjunctive therapy for treatment-resistant MDD, suggesting its novel mechanism targeting the opioid pathway may serve as a promising antidepressant devoid of abuse potential.
Posttraumatic Stress Disorder in Opioid Agonist Therapy: A Review
TLDR
Given the high comorbidity of PTSD and OUD, many individuals in OAT have PTSD and continue to experience symptoms of both disorders despite OAT treatment.
Buprenorphine treatment of refractory depression.
TLDR
A possible role for buprenorphine in treating refractory depression is suggested for the population of depressed patients who are unresponsive to or intolerant of conventional antidepressant agents.
Observational Evidence for Buprenorphine's Impact on Posttraumatic Stress Symptoms in Veterans With Chronic Pain and Opioid Use Disorder.
TLDR
This observational study is the first to report an incidental effect of buprenorphine compared to opioid therapy in improving PTSD symptoms in veterans.
KETAMINE FOR TREATMENT‐RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE
TLDR
This clinical review of ketamines will assess the evidence‐based use of ketamine and initial clinical implications of further development of a potentially novel treatment for rapid reduction of symptoms in depressed patients.
Pharmacologic treatment of acute and chronic stress following trauma: 2006.
  • J. Davidson
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2006
TLDR
The selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line therapy for PTSD; the roles of these and other drug classes including anticonvulsants, mood enhancers, atypical antipsychotic agents, benzodiazepines, alpha1-adrenergic antagonists, and beta-blockers in achieving improvement in PTSD symptom and outcome scores, achieving remission, and avoiding relapse are discussed.
Evaluation of Opioid Modulation in Major Depressive Disorder
TLDR
A combination of BUP and SAM showed antidepressant activity in subjects with MDD, and Balanced agonist–antagonist opioid modulation represents a novel and potentially clinically important approach to the treatment of MDD and other psychiatric disorders.
Effects of Buprenorphine on Responses to Emotional Stimuli in Individuals with a Range of Mood Symptomatology
TLDR
Low doses of buprenorphine may reduce some dimensions of responses to negative emotional stimuli in individuals high on depression or anxiety, while leaving other dimensions unaffected.
...
...